news

CUPERTINO, Calif., Feb. 9 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2008. Total revenues were $6.6 million for the three months ended December 31, 2008 and December 31, 2007. Net loss for the three months ended December 31, 2008 was $19.5 million, compared […]

CUPERTINO, Calif., Feb. 2 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, February 9th, 2009 at 4:30 p.m. EST (1:30 PST). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast of

CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics, Inc. (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of oxycodone. Based on its review, the FDA has determined that

CUPERTINO, Calif., Nov. 26 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. — 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3rd at 8:00 a.m. Eastern Time. — RBC Capital Markets 2008 Healthcare Conference on Wednesday, December

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2008. Total revenues were $6.6 million for the three months ended September 30, 2008, compared to $4.9 million for the same period in 2007. Net loss for the three months ended September 30, 2008

CUPERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the previously announced development and license agreement with Alpharma Ireland Limited, an affiliate of Alpharma Inc. (NYSE: ALO), granting such party the exclusive worldwide rights to develop and commercialize ELADUR(TM), DURECT’s investigational transdermal bupivacaine patch, has cleared review under the Hart-Scott-Rodino (HSR)

CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) — Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4th at 3:20 p.m. Eastern Time. — Barclays Capital Small & Mid-Cap Healthcare Forum on Thursday,

CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, November 3, 2008 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., Sept. 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into a development and license agreement with an affiliate of Alpharma Inc. (NYSE: ALO) granting such party the exclusive worldwide rights to develop and commercialize ELADUR(TM), DURECT’s investigational transdermal bupivacaine patch currently under development for the treatment of pain

CUPERTINO, Calif., Sept. 15 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Life Sciences Conference being held at the Grand Hyatt Hotel in New York. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on September 22 at 10:30 a.m. Eastern Time. (Logo: